MRIGlobal improves patient treatment outcomes by advancing the diagnosis of antimicrobial resistance.
Over time, bacteria and fungi can develop into stronger versions of themselves in order to defeat antibiotics. Each year, at least 23,000 people die as a result of antibiotic-resistant bacteria. MRIGlobal is working diligently with both public and private partners to conduct research and develop to build new tests and technologies to help fight antimicrobial resistance across the globe.
Discovery of new antimicrobial-resistant biomarkers to improve diagnostic technologies
Development and execution of state-of-the-art sequencing and bioinformatics methods
Research to understand the prevalence of zoonotic bacteria that could confer high levels of antimicrobial resistance
Joy Miller, Kyle Parker, and Stacee Varnum conduct antimicrobial testing in MRIGlobal’s CLIA laboratory.
MRIGlobal scientists conduct research, development, testing, and evaluation to improve antimicrobial resistance diagnostic technologies. Our goal is to advance these technologies into verification and validation phases of clinical product development.
Work With Us